Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tranexamic Acid for Bleeding in Metastatic Spinal Tumor Surgery
NCT06023212Phase 2Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Dec 2023
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, triple-blind trial of tranexamic acid in spinal tumor (2 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoints: Total Blood Loss and Intraoperative Blood Loss. Started Dec 2023; status: recruiting.
02
Drugs
tranexamic acid
03
Conditions
spinal tumor
Beyond the preview
Go deeper on NCT06023212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06023212.